FDA Approves Lilly's Omvoh™ for Ulcerative Colitis Treatment in Adults

The US Food and Drug Administration (FDA) has granted approval to Eli Lilly and Co for its drug, Omvoh, to treat adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. The drug is expected to be available in the US in the coming weeks. This approval allows Lilly to enter a market already occupied by competitors such as Abbvie, Pfizer, and Johnson & Johnson. The decision was based on positive results from late-stage studies showing the drug's effectiveness in improving symptoms compared to a placebo. Lilly has also received approval for the drug in Japan and the European Union this year. Ulcerative colitis is a condition characterized by inflammation and ulcers in the colon, leading to symptoms such as diarrhea, blood in stool, and abdominal pain.